J. Goldman & Co LP Buys Shares of 99,183 PolyPid Ltd. $PYPD

J. Goldman & Co LP acquired a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) in the second quarter, HoldingsChannel.com reports. The fund acquired 99,183 shares of the company’s stock, valued at approximately $504,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PYPD. AIGH Capital Management LLC increased its holdings in PolyPid by 18.7% in the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock worth $6,980,000 after acquiring an additional 250,615 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in PolyPid during the second quarter valued at $528,000. XTX Topco Ltd grew its position in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares in the last quarter. Renaissance Technologies LLC bought a new stake in PolyPid in the 1st quarter worth approximately $81,000. Finally, Jane Street Group LLC bought a new stake in PolyPid in the fourth quarter worth $66,000. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Price Performance

PYPD opened at $5.11 on Thursday. The firm has a market capitalization of $97.50 million, a PE ratio of -3.45 and a beta of 1.41. The business’s 50-day moving average is $4.80 and its two-hundred day moving average is $4.59. PolyPid Ltd. has a 1 year low of $3.06 and a 1 year high of $5.73.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. As a group, sell-side analysts expect that PolyPid Ltd. will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PYPD. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research note on Tuesday, July 21st. Weiss Ratings raised shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, Craig Hallum set a $12.00 price objective on PolyPid in a research note on Wednesday, July 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.33.

PolyPid Company Profile

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.